相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
Marija Brankovic et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Hepatic stellate cells in physiology and pathology
Dakota R. Kamm et al.
JOURNAL OF PHYSIOLOGY-LONDON (2022)
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M. Francque et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Non-alcoholic fatty liver disease
Elizabeth E. Powell et al.
LANCET (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets?
Alexandra Zisser et al.
BIOMEDICINES (2021)
Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS
Ji Min Oh et al.
THERANOSTICS (2021)
CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease
Denitra A. Breuer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2020)
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
Quentin M. Anstee et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
Guadalupe Garcia-Tsao et al.
JOURNAL OF HEPATOLOGY (2020)
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Jiyu Zhou et al.
NATURE COMMUNICATIONS (2020)
Differential fibrotic phenotypes of hepatic stellate cells within 3D liver organoids
Matthew Brovold et al.
BIOTECHNOLOGY AND BIOENGINEERING (2020)
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al.
DIABETES CARE (2020)
Nonalcoholic Steatohepatitis: A Review
Adam C. Sheka et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
Mengying Yang et al.
FRONTIERS IN PHARMACOLOGY (2020)
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease
Cyrielle Caussy et al.
NATURE COMMUNICATIONS (2019)
Transcriptional regulation of Hepatic Stellate Cell activation in NASH
Ann-Britt Marcher et al.
SCIENTIFIC REPORTS (2019)
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
Arun J. Sanyal et al.
HEPATOLOGY (2019)
Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity
Ali Aminian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Liver-Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug-Resistant Gene 2-Knockout Mice
Indu G. Rajapaksha et al.
HEPATOLOGY COMMUNICATIONS (2019)
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
Rohit Loomba et al.
HEPATOLOGY (2018)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2018)
Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large US Claims Database
Alina M. Allen et al.
HEPATOLOGY (2018)
Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study
Sayeed Ikramuddin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY (2018)
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes et al.
JOURNAL OF HEPATOLOGY (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
Triggering and resolution of inflammation in NASH
Susanne Schuster et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From two hit theory to multiple hit model
Yan-Lan Fang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension
Kwang Yong Shim et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2018)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
Treatment of NAFLD with diet, physical activity and exercise
Manuel Romero-Gómez et al.
JOURNAL OF HEPATOLOGY (2017)
TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-κB/STAT3 pathways
Aixiu Wang et al.
MOLECULAR IMMUNOLOGY (2017)
Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance
Ruth C. R. Meex et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Novel therapeutic strategies targeting ASK1 in NASH
Susanne Schuster et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Mechanisms of hepatic stellate cell activation
Takuma Tsuchida et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Renin angiotensin system in liver diseases: Friend or foe?
Ana Cristina Simoes e Silva et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Intestinal microbiota and nonalcoholic steatohepatitis
Katharina Brandl et al.
CURRENT OPINION IN GASTROENTEROLOGY (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World
Mehmet Sayiner et al.
CLINICS IN LIVER DISEASE (2016)
Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
Scott Friedman et al.
CONTEMPORARY CLINICAL TRIALS (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015
Haidong Wang et al.
LANCET (2016)
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
Len Verbeke et al.
SCIENTIFIC REPORTS (2016)
Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells
Nancy Magee et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Bariatric Surgery and Long-term Durability of Weight Loss
Matthew L. Maciejewski et al.
JAMA SURGERY (2016)
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Eric Lefebvre et al.
PLOS ONE (2016)
Roles of hepatic stellate cells in liver inflammation: a new perspective
Tomoko Fujita et al.
INFLAMMATION AND REGENERATION (2016)
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Hepatic Inflammation and Fibrosis: Functional Links and Key Pathways
Ekihiro Seki et al.
HEPATOLOGY (2015)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
Michal Pawlak et al.
JOURNAL OF HEPATOLOGY (2015)
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease
George B. Goh et al.
LIVER INTERNATIONAL (2015)
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
Jessica E. Potts et al.
PLOS ONE (2015)
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Tom Luedde et al.
GASTROENTEROLOGY (2014)
Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
William Peverill et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?
Zoon Tariq et al.
LIVER INTERNATIONAL (2014)
Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player
Lazar A. Bojic et al.
CURRENT OPINION IN LIPIDOLOGY (2013)
Immune and inflammatory pathways in NASH
Michal Ganz et al.
HEPATOLOGY INTERNATIONAL (2013)
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease
Yuki Kawano et al.
JOURNAL OF GASTROENTEROLOGY (2013)
From NAFLD to NASH to cirrhosis - new insights into disease mechanisms
Alexander Wree et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-κB in rats fed with high-fat diet
Sergio Henrique Sousa Santos et al.
PEPTIDES (2013)
Mechanisms for Insulin Resistance: Common Threads and Missing Links
Varman T. Samuel et al.
CELL (2012)
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Tatiana Kisseleva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques
Frank Tacke et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH
Meir Mizrahi et al.
JOURNAL OF INFLAMMATION RESEARCH (2012)
Nuclear Receptors in Liver Disease
Martin Wagner et al.
HEPATOLOGY (2011)
PROGRESSION OF NAFLD IN HUMANS IS ASSOCIATED WITH THE ACTIVATION OF THE RENIN-ANGIOTENSIN SYSTEM
J. Vergniol et al.
JOURNAL OF HEPATOLOGY (2011)
Human Fatty Liver Disease: Old Questions and New Insights
Jonathan C. Cohen et al.
SCIENCE (2011)
Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis
Herbert Tilg et al.
HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oxidative Stress-Mediated Mitochondrial Dysfunction Contributes to Angiotensin II-Induced Nonalcoholic Fatty Liver Disease in Transgenic Ren2 Rats
Yongzhong Wei et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease
Luca Miele et al.
HEPATOLOGY (2009)
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats
Jorge E. Toblli et al.
OBESITY (2008)
The grateful dead:: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity
Michael T. Lotze et al.
IMMUNOLOGICAL REVIEWS (2007)
TLR4 enhances TGF-β signaling and hepatic fibrosis
Ekihiro Seki et al.
NATURE MEDICINE (2007)
Effect of fetuin, a TGFβ antagonist and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and fibrotic parameters in fibrosis
Monica Verma-Gandhu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Metabolic endotoxemia initiates obesity and insulin resistance
Patrice D. Cani et al.
DIABETES (2007)
Selective targeting of pentoxifylline platinum-based to hepatic stellate cells using a novel linker technology
T Gonzalo et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Adipogenic transcriptional regulation of hepatic stellate cells
HY She et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
SL Friedman
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
